[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note",
    "summary": "Bristol Myers Squibb (BMY) concluded the recent trading session at $48.66, signifying a -2.19% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=bf520f3ca3365395b9cf68cbde535a9e227067810e8df42604c1a72b0372b274",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750110301,
      "headline": "Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note",
      "id": 135318074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (BMY) concluded the recent trading session at $48.66, signifying a -2.19% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=bf520f3ca3365395b9cf68cbde535a9e227067810e8df42604c1a72b0372b274"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=1b3f450b360c943e4655b55443d0c130286608dc551310ea9b0f96d2eb91af01",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750091880,
      "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
      "id": 135333423,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=1b3f450b360c943e4655b55443d0c130286608dc551310ea9b0f96d2eb91af01"
    }
  },
  {
    "ts": null,
    "headline": "BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium",
    "summary": "Discover why BeOne Medicines (BEIGF) is a strong Buy with growth driven by Brukinsa, Tevimbra, and a promising oncology pipeline.",
    "url": "https://finnhub.io/api/news?id=48d2aa2b51419359ce3895ab9e676565b220c2273b8f4d8975dc223b1df171fe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750071968,
      "headline": "BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium",
      "id": 135305491,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160714898/image_2160714898.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover why BeOne Medicines (BEIGF) is a strong Buy with growth driven by Brukinsa, Tevimbra, and a promising oncology pipeline.",
      "url": "https://finnhub.io/api/news?id=48d2aa2b51419359ce3895ab9e676565b220c2273b8f4d8975dc223b1df171fe"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)",
    "summary": "PRINCETON, N.J., June 16, 2025--BMS Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi",
    "url": "https://finnhub.io/api/news?id=653d7fa8501adf4362b7248b68c7be71b8f41b1229dced195831bb9d98be53ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750071540,
      "headline": "Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)",
      "id": 135300102,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., June 16, 2025--BMS Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi",
      "url": "https://finnhub.io/api/news?id=653d7fa8501adf4362b7248b68c7be71b8f41b1229dced195831bb9d98be53ac"
    }
  },
  {
    "ts": null,
    "headline": "2 Beaten-Down Dividend Stocks to Buy Right Now",
    "summary": "Target has growth opportunities, particularly in its digital sales business, and boasts an impressive dividend profile.  Bristol Myers Squibb can overcome recent and future patent cliffs thanks to newer approvals.",
    "url": "https://finnhub.io/api/news?id=7e77a2b01ac4a63f82f6e7d068e83092403eb49ab3813e2b0350b6bf4a9a34d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750062300,
      "headline": "2 Beaten-Down Dividend Stocks to Buy Right Now",
      "id": 135300103,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Target has growth opportunities, particularly in its digital sales business, and boasts an impressive dividend profile.  Bristol Myers Squibb can overcome recent and future patent cliffs thanks to newer approvals.",
      "url": "https://finnhub.io/api/news?id=7e77a2b01ac4a63f82f6e7d068e83092403eb49ab3813e2b0350b6bf4a9a34d0"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: positive phase 2 data in lymphoma",
    "summary": "Bristol Myers Squibb announces positive results from the primary analysis of the TRANSCEND FL cohort, a Phase 2 study evaluating Breyanzi in patients with relapsed or refractory marginal zone lymphoma...",
    "url": "https://finnhub.io/api/news?id=043f96098da6c390bdeac11574595e6bb99bcdcec21d2532519a7e6745ad0665",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750060656,
      "headline": "Bristol Myers: positive phase 2 data in lymphoma",
      "id": 135299919,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announces positive results from the primary analysis of the TRANSCEND FL cohort, a Phase 2 study evaluating Breyanzi in patients with relapsed or refractory marginal zone lymphoma...",
      "url": "https://finnhub.io/api/news?id=043f96098da6c390bdeac11574595e6bb99bcdcec21d2532519a7e6745ad0665"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Reports Strong Breyanzi Results in MZL Cohort of TRANSCEND FL Trial",
    "summary": "Bristol-Myers Squibb Co: * BRISTOL MYERS SQUIBB PRESENTS FIRST DATA FROM THE MARGINALZONELYMPHOMA COHORT OF THE TRANSCEND FL TRIAL DEMONSTRATING DEEP ANDDURABLE RESPONSES WITH...",
    "url": "https://finnhub.io/api/news?id=9f43a4c384a6a3f950914b7783d9ac6ffb30c28706de2910ddad40adfbe4f4ab",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750057415,
      "headline": "Bristol Myers Squibb Reports Strong Breyanzi Results in MZL Cohort of TRANSCEND FL Trial",
      "id": 135299582,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol-Myers Squibb Co: * BRISTOL MYERS SQUIBB PRESENTS FIRST DATA FROM THE MARGINALZONELYMPHOMA COHORT OF THE TRANSCEND FL TRIAL DEMONSTRATING DEEP ANDDURABLE RESPONSES WITH...",
      "url": "https://finnhub.io/api/news?id=9f43a4c384a6a3f950914b7783d9ac6ffb30c28706de2910ddad40adfbe4f4ab"
    }
  }
]